Alpha-gal specific IgG immune response after implantation of bioprostheses

Thoracic and Cardiovascular Surgeon

Volumn 57, Issue 4, 2009, Pages 191-195

  Mangold, A ^a   Szerafin, T ^b   Hoetzenecker, K ^a   Hacker, S ^a   Lichtenauer, M ^a   Niederpold, T ^a   Nickl, S ^a   Dworschak, M ^a   Blumer, R ^a   Auer, J ^c   Ankersmit, H J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c St Josef Hospital Braunau   (Austria)

Author keywords

Alpha Gal; Bioprosthesis heart valves; Heart valve surgery; Mechanical heart valves; Xenograft

Indexed keywords

CELL NUCLEUS ANTIGEN; DAPI ANTIGEN; IB4 ANTIGEN; IMMUNOGLOBULIN G; LECTIN; UNCLASSIFIED DRUG; ALPHA GALACTOSIDASE; EPITOPE;

ADULT; AGED; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BIOPROSTHESIS; BLOOD SAMPLING; CARDIAC PATIENT; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART SURGERY; HEART VALVE PROSTHESIS; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REOPERATION; SWINE; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CATTLE; HEART VALVE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MIDDLE AGED; TIME;

AGED; ALPHA-GALACTOSIDASE; ANIMALS; ANTIBODY SPECIFICITY; BIOPROSTHESIS; CATTLE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HEART VALVE PROSTHESIS; HEART VALVES; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POSTOPERATIVE PERIOD; SWINE; TIME FACTORS;

EID: 70350447796     PISSN: 01716425     EISSN: 14391902     Source Type: Journal    
DOI: 10.1055/s-0029-1185395     Document Type: Article

References (31)

1. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1-3Gal epitope in primates. Proc Natl Acad Sci USA 1987; 84:1369-1373
2. Galili U,Macher BA, Buehler J, Shohet SB. Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1-3)-linked galactose residues. J Exp Med 1985; 162: 573-582
3. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med 1984; 160: 1519-1531
4. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IF. Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391-11395
5. Galili U. Xenotransplantation and ABO incompatible transplantation: the similarities they share. Transfus Apher Sci 2006; 35: 45-58
6. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 1988; 56: 1730-1737
7. Gallili U. The alpha-gal epitope (Gal alpha 1-3Gal beta 1-4GlcNAc-R) in xenotransplantation. Biochimie 2001; 83: 557-563
8. Bonow RO, Carabello BA, Kanu C, de Leon Jr AC, Faxon DP, Freed MD et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006; 114: e84-e231
9. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000; 36: 1152-1158
10. Akins CW, Hilgenberg AD, Vlahakes GJ, MacGillivray TE, Torchiana DF, Madsen JC. Results of bioprosthetic versus mechanical aortic valve replacement performed with concomitant coronary artery bypass grafting. Ann Thorac Surg 2002; 74: 1098-1106
11. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg 2005; 79: 1072-1080
12. Human P, Zilla P. Inflammatory and immune processes: the neglected villain of bioprosthetic degeneration? J Long Term Eff Med Implants 2001; 11: 199-220
13. Zilla P, Brink J, Human P, Bezuidenhout D. Prosthetic heart valves: catering for the few. Biomaterials 2008; 29: 385-406
14. Laitinen L. Griffonia simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem J 1987; 19: 225-234
15. Konakci KZ, Bohle B, Blumer R, Hoetzenecker W, Roth G, Moser B et al. Alpha-Gal on bioprostheses: xenograft immune response in cardiac surgery. Eur J Clin Invest 2005; 35: 17-23
16. Stavnezer J. Immunoglobulin class switching. Curr Opin Immunol 1996; 8: 199-205
17. Ishizaka T, Ishizaka K, Salmon S, Fudenberg H. Biologic activities of aggregated gamma-globulin. 8. Aggregated immunoglobulins of different classes. J Immunol 1967; 99: 82-91
18. Schumaker VN, Calcott MA, Spiegelberg HL, Muller-Eberhard HJ. Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry 1976; 15: 5175-5181
19. Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991; 21: 11-16
20. Bredius RG, Fijen CA, De Haas M, Kuijper EJ, Weening RS, Van de Winkel JG et al. Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3- opsonized bacteria and erythrocytes. Immunology 1994; 83: 624-630
21. Huizinga TW, Kerst M, Nuyens JH, Vlug A, von dem Borne AE, Roos D et al. Binding characteristics of dimeric IgG subclass complexes to human neutrophils. J Immunol 1989; 142: 2359-2364
22. Parren PW,Warmerdam PA, Boeije LC, Arts J,Westerdaal NA, Vlug A et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 1992; 90: 1537-1546
23. Salgaller ML, Bajpai PK. Immunogenicity of glutaraldehyde-treated bovine pericardial tissue xenografts in rabbits. J Biomed Mater Res 1985; 19: 1-12
24. Rocchini AP,Weesner KM, Heidelberger K, Keren D, Behrendt D, Rosenthal A. Porcine xenograft valve failure in children: an immunologic response. Circulation 1981; 64: II162-II171
25. Manji RA, Zhu LF, Nijjar NK, Rayner DC, Korbutt GS, Churchill TA et al. Glutaraldehyde-fixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection. Circulation 2006;114: 318-327
26. Chen RH, Kadner A, Mitchell RN, Adams DH. Fresh porcine cardiac valves are not rejected in primates. Thorac Cardiov Surg 2000; 119: 1216-1220
27. Farivar RS, Filsoufi F, Adams DH. Mechanisms of Gal(alpha)1-3Gal(beta) 1-4GlcNAc-R (alphaGal) expression on porcine valve endothelial cells. Thorac Cardiovasc Surg 2003; 125: 306-314
28. Kasimir MT, Rieder E, Seebacher G,Wolner E,Weigel G, Simon P. Presence and elimination of the xenoantigen gal (alpha1, 3) gal in tissue-engineered heart valves. Tissue Eng 2005; 11: 1274-1280
29. Bonow RO, Carabello BA, Chatterjee K, de Leon Jr AC, Faxon DP, Freed MD et al. Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118: e523-e661
30. Ye J, Cheung A, Lichtenstein SV, Pasupati S, Carere RG, Thompson CR et al. Six-month outcome of transapical transcatheter aortic valve implantation in the initial seven patients. Eur J Cardiothorac Surg 2007; 31: 16-21
31. Walther T, Falk V, Kempfert J, Borger MA, Fassl J, Chu MWet al. Transapical minimally invasive aortic valve implantation; the initial 50 patients. Eur J Cardiothorac Surg 2008; 33: 983-988